Ray Dalio's AMGN Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 11,295 shares of Amgen Inc. (AMGN) worth $3.19 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in AMGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 152,566 shares. Largest reduction occurred in Q3 2023, reducing 138,503 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Amgen (AMGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amgen (AMGN) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +83,245 | Add 0.00% | 83,244 | $98.66 |
| Q3 2013 | -83,244 | Sold Out | 0 | $0.00 |
| Q4 2013 | +7,513 | New Buy | 7,513 | $114.07 |
| Q1 2014 | -7,513 | Sold Out | 0 | $0.00 |
| Q1 2015 | +4,373 | New Buy | 4,373 | $159.84 |
| Q2 2015 | +38,200 | Add 873.54% | 42,573 | $153.52 |
| Q3 2015 | +19,460 | Add 45.71% | 62,033 | $138.31 |
| Q4 2015 | -62,033 | Sold Out | 0 | $0.00 |
| Q2 2016 | +38,300 | New Buy | 38,300 | $152.14 |
| Q3 2016 | -38,300 | Sold Out | 0 | $0.00 |
| Q1 2017 | +51,460 | New Buy | 51,460 | $164.07 |
| Q2 2017 | -25,044 | Reduce 48.67% | 26,416 | $172.24 |
| Q3 2017 | +32,857 | Add 124.38% | 59,273 | $186.44 |
| Q4 2017 | -43,286 | Reduce 73.03% | 15,987 | $173.89 |
| Q1 2018 | +46,512 | Add 290.94% | 62,499 | $170.48 |
| Q2 2018 | -62,499 | Sold Out | 0 | $0.00 |
| Q4 2020 | +8,200 | New Buy | 8,200 | $229.88 |
| Q1 2021 | -7,150 | Reduce 87.20% | 1,050 | $248.57 |
| Q2 2021 | +28,049 | Add 2671.33% | 29,099 | $243.75 |
| Q3 2021 | +8,743 | Add 30.05% | 37,842 | $212.65 |
| Q4 2021 | -11,964 | Reduce 31.62% | 25,878 | $224.98 |
| Q1 2022 | +28,510 | Add 110.17% | 54,388 | $241.82 |
| Q2 2022 | +398 | Add 0.73% | 54,786 | $243.29 |
| Q3 2022 | -44,542 | Reduce 81.30% | 10,244 | $225.40 |
| Q4 2022 | +1,583 | Add 15.45% | 11,827 | $262.64 |
| Q1 2023 | +152,566 | Add 1289.98% | 164,393 | $241.75 |
| Q2 2023 | +1,835 | Add 1.12% | 166,228 | $222.02 |
| Q3 2023 | -138,503 | Reduce 83.32% | 27,725 | $268.76 |
| Q4 2023 | +116,758 | Add 421.13% | 144,483 | $288.02 |
| Q1 2024 | -128,065 | Reduce 88.64% | 16,418 | $284.32 |
| Q2 2024 | -7,692 | Reduce 46.85% | 8,726 | $312.45 |
| Q3 2024 | -5,354 | Reduce 61.36% | 3,372 | $322.21 |
| Q4 2024 | -1,957 | Reduce 58.04% | 1,415 | $260.64 |
| Q1 2025 | -1,415 | Sold Out | 0 | $0.00 |
| Q2 2025 | +7,435 | New Buy | 7,435 | $279.21 |
| Q3 2025 | +3,860 | Add 51.92% | 11,295 | $282.20 |
Ray Dalio's Amgen Investment FAQs
Ray Dalio first purchased Amgen Inc. (AMGN) in Q2 2013, acquiring 83,244 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Amgen Inc. (AMGN) for 36 quarters since Q2 2013.
Ray Dalio's largest addition to Amgen Inc. (AMGN) was in Q1 2023, adding 164,393 shares worth $39.74 M.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 11,295 shares of Amgen Inc. (AMGN), valued at approximately $3.19 M.
As of the Q3 2025 filing, Amgen Inc. (AMGN) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Amgen Inc. (AMGN) was 166,228 shares, as reported at the end of Q2 2023.